RxDoctor Payments Data

Devin Gattey, MD

Ophthalmology · Aloha, ORNPI 1194776484

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (40.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 51.0% of the total. Reporting peaked in 2019 at $2,257 and has fallen 95.0% since, to $112 in 2025.

$4,505in general payments, 2019–2025

Across 34 payments — averaging $132.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Eli Lilly$2K
  • Alcon$619
  • Lombart Brothers, Inc.$45
  • Aerie Pharmaceuticals, Inc.$19
  • Sun Pharmaceutical Industries Inc.$14
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$1,50033%
  • Travel & lodging$1,82240%
  • Food & beverage$1,18326%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,505 in reported general payments places this provider in the 85th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon

Medicare billing

Part B allowed, 2024
$84,903
Medicare patients
394
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$32,784
LumiganBimatoprost15$10,712
Cyclosporine15$7,533
VyzultaLatanoprostene Bunod17$7,136
Latanoprost412$6,291
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat151$3,025
Timolol Maleate168$2,394
Prednisolone Acetate58$2,126
Ketorolac Tromethamine41$979
Dorzolamide Hcl42$861
Brimonidine Tartrate62$761
Ofloxacin39$477
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$352
Levobunolol Hcl11$348
ErythromycinErythromycin Base13$151

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Aloha

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →